Performance in Initiating HRA Approved Studies - Q1 2019/20

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	delay correspond
		Conventional versus Minimally Invasive extra-corporeal circulation in	10/07/2010	10/0//2010	23/11/2017	13/11/2010	14/11/2010	01/01/2013	21/01/2013	
17/SW/0250	222991	patients undergoing Cardiac Surgery: a randomised controlled trial (COMICS)								Neither
		A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of	20/07/2018	21/07/2018	21/08/2018	20/08/2018	23/08/2018	23/08/2018	24/08/2018	
		VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are								
18/NE/0266	241641	Homozygous or Heterozygous for the F508del Mutation								
İ		Use of right ventricular conductance catheter guidance to optimise balloon	19/08/2018	19/08/2018		13/02/2019	13/02/2019	13/02/2019		
10/55/01/02	220500	pulmonary angioplasty as a non surgical treatment of chronic								
18/EE/0162	229599	thromboembolic pulmonary hypertension. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial	09/08/2018	07/09/2018	29/06/2018	17/00/2019	19/09/2018	19/09/2018	02/10/2018	+
18/NI/0060	242168	to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis	09/08/2018	07/09/2018	29/00/2018	17/09/2016	19/09/2018	19/09/2018	02/10/2018	
	2.2200	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the	06/08/2018	13/08/2018	18/09/2018	12/12/2018	18/12/2018	15/05/2019	29/05/2019	
		Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary	, ,	, , , , ,	, , , , , ,	, ,	, ,	., ,	.,,	
18/LO/1258	248312	Fibrosis								Neither
17/LO/1170		A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate	29/08/2018	06/09/2018	02/08/2017	05/12/2018	10/12/2018	31/01/2019		
		the efficacy and safety of macitentan in subjects with heart failure with								
	219279	preserved ejection fraction and pulmonary vascular disease			/ /			/ /	/	-
18/NW/0074	226216	Cryoballoon Pulmonary Vein Isolation as First line treatment for Typical Atrial Flutter (CRAFT)	11/10/2018	01/11/2018	28/02/2018	30/01/2019	01/02/2019	11/02/2019	13/03/2019	
16/11/00/4	230310	OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation	20/03/2018	26/10/2018	25/10/2018	00/04/2010	11/04/2019			
		Compared to Angiography: a Multicenter	20/03/2018	20/10/2018	23/10/2018	03/04/2013	11/04/2019			
18/LO/1193	242628	Randomized TriaL in PCI								Sponsor
2, 2, 22		A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre,	17/10/2017	01/08/2018	04/12/2018	19/12/2018	21/12/2018	07/01/2019	23/05/2019	
		Prospective Study to Assess Efficacy of Riociguat in Patients With Operable								
		CTEPH Prior to Pulmonary Endarterectomy With High Preoperative								
18/YH/0330	236317	Pulmonary Vascular Resistance								Neither
	247000	Developing a non-contact sleep apnoea detector, suitable for home studies -	20/04/2018	21/12/2018	30/11/2018	09/01/2019	09/01/2019	09/01/2019	09/01/2019	
18/LO/1848	247009	The Safescan study Effectiveness of the GRACE risk score on the management and outcome of	11/01/2018	31/01/2019	21/03/2017	17/05/2010	08/05/2019	06/06/2019	10/06/2019	
14/NE/1180	145170	patients hospitalised with non-ST elevation acute coronary syndrome.	11/01/2018	31/01/2019	21/03/2017	17/03/2019	08/03/2019	00/00/2019	10/00/2019	Sponsor
	1.527	IDL-2965 ? A Phase I, Randomized, Double-blind, Placebo-controlled, Single	26/02/2019	26/02/2019						орольо.
		and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in	.,.,	, , ,						
19/NW/0001	253853	Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis								Neither
		A Phase 3, randomized, double-blind, parallel-group, placebo controlled	22/10/2018	22/10/2018						
		multicenter study to evaluate the efficacy and safety of two doses of								
40/00/0004	25	GLPG1690 in addition to local standard of care for minimum 52 weeks in]				
19/SC/0034	254823	subjects with idiopathic pulmonary fibrosis. A randomised controlled trial of high-flow nasal oxygen (HFNO) vs. standard	22/14/2010	15/01/2010		10/04/2010	00/05/2010	00/05/2010	05/06/2010	
		oxygen therapy in patients undergoing transfemoral transcatheter aortic	22/11/2018	15/01/2019		18/04/2019	08/05/2019	08/05/2019	05/06/2019	
19/EE/0104	255651	valve implantation (TAVI) under conscious sedation.								
	255051	An open-label, pilot study to assess safety, tolerability, pharmacokinetics and	09/05/2018	18/10/2018						
		effects of inhaled PC945 in the pre-emptive treatment of Aspergillus		-, -,]				
18/EE/0091	256412	fumigatus colonisation in lung transplant recipients								Neither

		Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and	14/02/2019	13/03/2019	17/06/2019			
		Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in						
19/EM/0101	260487	Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial						
		EluNIR Ridaforolimus Eluting Coronary Stent System in patients at high	22/05/2019	12/06/2019				
19/NI/0110	260538	bleeding risk (HBR)? EluNIR HBR study						